Expert Perspective on Long-Term Open-Label Extension Data for Dupilumab in the Treatment of Atopic Dermatitis

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, review the burden of atopic dermatitis and discuss how they talk to patients about the impact their disease has on their lives.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, evaluate the effect of the rapidly changing therapeutic landscape in atopic dermatitis.

Thought leaders share strategies for talking to patients about the importance of treatment adherence in the long-term management of atopic dermatitis.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, review the design of the LIBERTY-AD open-label extension trial and share clinical context regarding safety findings.

Continuing their discussion about safety, Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, take a closer look at conjunctivitis data from the long-term use of dupilumab

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, discuss the relevance of the 4-year efficacy data for dupilumab in adults with moderate to severe atopic dermatitis, with a focus on IGA and EASI scores.

Continuing their discussion about efficacy, Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, review long-term results on pruritus. Additionally, they explore data for patients who switched from weekly to every-other-week dupilumab treatment.

Thought leaders discuss the importance of rapid onset of action in atopic dermatitis care amid the backdrop of compelling 4-year efficacy and safety data for dupilumab.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, review the impact of the open-label extension data on the current atopic dermatitis landscape.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, talk about how clinical approaches and understanding of risk/benefit profiles are evolving in light of the emerging long-term data.